US equities
|
SPCX
$166.49
▲+4.74%
NVDA
$236.66
▲+1.16%
MU
$1,064.21
▼-0.99%
TSLA
$377.48
▲+1.86%
MSFT
$525.66
▲+1.57%
SNDK
$1,710.49
▼-0.55%
INTC
$117.08
▼-1.88%
META
$745.14
▲+2.34%
SPCX
$166.49
▲+4.74%
NVDA
$236.66
▲+1.16%
MU
$1,064.21
▼-0.99%
TSLA
$377.48
▲+1.86%
MSFT
$525.66
▲+1.57%
SNDK
$1,710.49
▼-0.55%
INTC
$117.08
▼-1.88%
META
$745.14
▲+2.34%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Noveris Health Sciences
(OP:
MYCOF
)
0.7300
UNCHANGED
Last Price
Updated: 12:48 PM EDT, Aug 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Noveris Health Sciences
< Previous
1
2
3
4
5
6
7
Next >
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
↗
May 23, 2023
Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application...
Via
Benzinga
Mydecine's Q1 2023 Reports Shows Decline In Assets And R&D, Increase In Net Loss And Accumulated Deficit
↗
May 17, 2023
Psychedelics biotech Mydecine Innovations Group (OTC: MYCOF) shared its condensed interim (unaudited) financial results for three months ended March 31, 2023. First quarter numbers:
Via
Benzinga
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Results of Annual General Shareholders Meeting
May 11, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Mydecine Reports its 2023 Annual General Shareholders' Meeting Results
May 10, 2023
From
Mydecine Innovations Group Inc.
Via
GlobeNewswire
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
↗
May 01, 2023
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued
Via
Benzinga
New Set Of MDMA Analogs To Hit The Clinic: These Are The Latest Positive Findings
↗
April 25, 2023
Psychedelics biotech Mydecine Innovations Group (OTC: MYCOF) is advancing the development of its novel compounds family of next-gen MDMA analogs. So far, Mydecine's compounds show promising...
Via
Benzinga
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Positive Preclinical Results on MYCO-006 Series
April 24, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues
April 24, 2023
From
Mydecine Innovations Group Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Closes on Share Subscription Agreement
April 20, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Filing of Prospectus Supplement, First Tranche Closing
April 11, 2023
Via
Investor Brand Network
Mydecine: 2022 Financials & Business Update By Next-Gen Psychedelics Producer, Smoke Cessation Trial And More
↗
April 03, 2023
Colorado and Leiden-based biotech company Mydecine Innovations Group (OTC: MYCOF) has shared its financial results and business highlights for the period ended December 31, 2022. In ciphers:
Via
Benzinga
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Issues Corporate Update
April 03, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Mydecine Innovations Group Provides Corporate Update
April 03, 2023
From
Mydecine Innovations Group Inc.
Via
GlobeNewswire
Mydecine Reports Financial Results for the Year Ended December 2022
March 31, 2023
From
Mydecine Innovations Group Inc.
Via
GlobeNewswire
BioMedNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Reports on Debt Settlement Agreements
March 06, 2023
Via
Investor Brand Network
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
↗
January 03, 2023
What a year for psychedelics!
Via
Benzinga
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
↗
December 19, 2022
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.
Via
Benzinga
Psychedelic Company Sale: Mydecine Gets Over $2.5M For Wholly-Owned Tech Subsidiary Business
↗
December 13, 2022
Mydecine Innovations Group Inc.
Via
Benzinga
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Closes Sale of Mindleap Health Inc.
December 12, 2022
Via
Investor Brand Network
Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.
December 12, 2022
From
Mydecine Innovations Group Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Filing of Prospectus Supplement, Closing Under Share Subscription Agreement
November 29, 2022
Via
Investor Brand Network
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
↗
November 21, 2022
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy
Via
Benzinga
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Filing of Prospectus Supplement, Closes Share Subscription Agreement
November 21, 2022
Via
Investor Brand Network
Mydecine's Q3 Financials & Update, Sustained Target On Smoking Cessation For Next 12 Months
↗
November 15, 2022
Mydecine Innovations Group (OTC: MYCOF), the psychedelics biotech company headquartered in Denver, Colorado with international offices in the Netherlands, reported its financial results and business...
Via
Benzinga
Mydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022
November 14, 2022
From
Mydecine Innovations Group Inc.
Via
GlobeNewswire
Psychedelics Biotechs Clearmind And Mydecine Share Consolidation And Subscription Agreements
↗
September 26, 2022
In connection with recent stock splits, psychedelics biotech Clearmind Medicine Inc.
Via
Benzinga
PsychedelicNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Closing Under Share Subscription Agreement, Appointment of New CFO
September 23, 2022
Via
Investor Brand Network
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Files Prospectus Supplement, Closes First Tranche Under Subscription Agreement
September 15, 2022
Via
Investor Brand Network
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Enters LOI for Sale of Mindleap Health
September 01, 2022
Via
Investor Brand Network
World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them
↗
August 30, 2022
The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
